鷹瞳科技-B(02251.HK)香港發售股份獲充分超額認購 預計11月5日掛牌上市
格隆匯11月4日丨鷹瞳科技-B(02251.HK)發佈公吿，公司全球發售2226.72萬股股份，其中香港發售股份222.68萬股，國際發售股份2004.04萬股，另有15%超額配股權；發售價已釐定為每股發售股份75.1港元，每手買賣單位100股；瑞銀及中信證券為聯席保薦人；預期股份將於2021年11月5日於聯交所主板掛牌上市。
香港公開發售項下初步提呈發售的香港發售股份已獲充分超額認購。合共接獲14,309份有效申請，認購合共1375.78萬股香港發售股份，相當於香港公開發售項下初步可供認購的香港發售股份總數約6.18倍。國際發售項下初步提呈的發售股份已獲適度超額認購，相當於國際發售項下初步可供認購發售股份總數的約2.9倍。基於每股75.1港元的發售價，及根據基石投資協議，基石投資者認購的發售股份數目現已確定。CloudAlpha、廣發基金、常春藤、Lake Bleu Prime、LAV、LMR、OrbiMed及WT各自已分別認購155.37萬股、103.58萬股、72.5萬股、51.79萬股、103.58萬股、77.68萬股、51.79萬股及103.58萬股，合共719.87萬股發售股份。
按發售價每股75.1港元計算，公司將收取的全球發售所得款項淨額估計約為15.664億港元。公司擬將全球發售所得款項約50.0%分配予集團的核心產品Airdoc-AIFUNDUS的持續優化、開發及商業化；約19.0%將用於資助集團硬件設備的研發及生產；約10.0%將用於資助集團正在進行的及未來的健康風險評估解決方案的研發；約6.0%將用於集團產品組合的開發，以豐富集團人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案；約5.0%將用於為集團與學術及研究機構就聯合研究項目進行的合作提供資金；及約10.0%將用於營運資金及一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
